multiple ascending doses of survodutide over 16 weeks produced mean bodyweight decreases of up to 14.1% (2.4 mg survodutide twice weekly [biw] vs 0.3% with placebo) [15]
Epithelial cell protection from NSAIDs and ethanol, mucosal barrier integrity maintenance, anastomosis and fistula healing models (colo-cutaneous, recto-vaginal), ulcer healing mechanisms
Timing: Dosing is most often administered in the evening, shortly before bedtime, to align with its hypothesized promotion of SWS and natural circadian rhythms
Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation
Endocrinology 151 , 14411450 (2010)
K., Harper, M.-E., & Cuperlovic-Culf, M